Valid concern! From the Ann: Investor Webinar Presentation on the 17/11/21 they stated:
Mind you this includes both the FIH trial for Alzheimer's and the FIP trial for Glaucoma. It would be very disappointing should a CR be required before either of these outcomes. $3m spend in the last quarter on pre-clinical activities seems high, lets hope some of this is upfront expenditure for the trials
- Forums
- ASX - By Stock
- NSB
- Ann: Quarterly Activities/Appendix 4C Cash Flow Report
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-4
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NSB (ASX) to my watchlist
|
|||||
Last
4.5¢ |
Change
-0.001(2.17%) |
Mkt cap ! $6.507M |
Open | High | Low | Value | Volume |
4.6¢ | 4.6¢ | 4.5¢ | $31.09K | 689.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 401 | 4.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.0¢ | 83911 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 25000 | 0.044 |
1 | 49400 | 0.042 |
1 | 800000 | 0.041 |
2 | 305000 | 0.040 |
2 | 225000 | 0.036 |
Price($) | Vol. | No. |
---|---|---|
0.050 | 83911 | 3 |
0.051 | 83976 | 2 |
0.053 | 209261 | 1 |
0.055 | 50000 | 1 |
0.069 | 50001 | 1 |
Last trade - 14.21pm 23/08/2024 (20 minute delay) ? |
Featured News
NSB (ASX) Chart |
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online